Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Blood Test May Help Predict Breast Cancer Relapse

2015-08-31
|
Page View:

       A simple blood test may, in the future, provide breast cancer patients with an early warning of the disease returning after chemotherapy and surgery. Conducted repeatedly, a blood test capable of profiling circulating tumor DNA can track genetic changes that occur over time, picking up signs that a treated cancer—in this case, breast cancer—is about to return. The blood test, a so-called liquid biopsy, detects mutations in DNA shed by cancer cells, and it can be used to predict breast cancer relapse about eight months before tumors become visible on hospital scans.

Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.

   

      A liquid biopsy not only spares patients the invasive procedures needed to collect solid tumor samples but can also be repeated easily, catching key mutations that cancer accumulates as it develops and spreads. To create a liquid biopsy for breast cancer, scientists at the Institute of Cancer Research in London developed a polymerase chain reaction (PCR) test that is sensitive to the sorts of mutations common to many types of breast cancer.

  breast cancer.webp

       The researchers described their test on August 26 in the journal Science Translational Medicine article entitled, “Mutation tracking in circulating tumor DNA (ctDNA) predicts relapse in early breast cancer.” The report detailed the analysis of circulating tumor DNA in plasma and showed how it might be used to enable monitoring for minimal residual disease (MRD) in breast cancer.

  

       “In a prospective cohort of 55 early breast cancer patients receiving neoadjuvant chemotherapy, detection of ctDNA in plasma after completion of apparently curative treatment—either at a single postsurgical time point or with serial follow-up plasma samples—predicted metastatic relapse with high accuracy,” wrote the authors. “Mutation tracking in serial samples increased sensitivity for the prediction of relapse, with a median lead time of 7.9 months over clinical relapse.”


Related Articles:

Spicy Food Could Inhibit Breast Cancer Cells

Fighting Treatment-Resistant Breast Cancer Using RNA Nanoparticles

Breast Cancer Mortality Rates Declined Globally

   

       The authors added that analysis of ctDNA could define the genetic events of MRD and that MRD sequencing predicted the genetic possibilities of the subsequent metastatic relapse more accurately than sequencing of primary cancer. They also pointed out that their test could identify the mutations likely to prove lethal to individual patients, raising the possibility of tailored treatments.

  

       “We have shown how a simple blood test has the potential to accurately predict which patients will relapse from breast cancer much earlier than we can currently,” said study leader Nicholas Turner, Ph.D., team leader in molecular oncology at the Institute of Cancer Research. “We also used blood tests to build a picture of how the cancer was evolving, and this information could be invaluable to help doctors select the correct drugs to treat cancer.

  

       “Ours is the first study to show that these blood tests could be used to predict relapse. It will be some years before the test could be available in hospitals, but we hope to bring this date closer by conducting much larger clinical trials starting next year.”

  

       “We are moving into an era of personalized medicine for cancer patients,” added Paul Workman, Ph.D., chief executive of the Institute of Cancer Research. “This test could help us stay a step ahead of cancer by monitoring how it is changing and picking treatments that exploit the weakness of the tumor. It is fantastic that we can get a comprehensive insight into what is going on in cancer all over the body, without the need for invasive biopsies.”

  

    Building on these results, the team plans a more extensive study next year. It could be a few years before blood tests are widely available to cancer survivors.

Return
Relevant newsRelevant news